The Real-World Efficacy and Safety of Anlotinib Treatment for Advanced Non-Small Cell Lung Cancer

被引：0
|
作者：
Wang, F. [1 ]
Jin, F. [1 ]
Wang, S. [1 ]
Zhu, Y. [1 ]
机构：
[1] Peking Univ, Dept Oncol, Shenzhen Hosp, Shenzhen, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P86.04
引用
收藏
页码：S673 / S673
页数：1
相关论文
共 50 条
  • [41] Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer
    Hozefa A. Divan
    Marisa A. Bittoni
    Ashok Krishna
    David P. Carbone
    [J]. BMC Cancer, 24
  • [42] Real-world clinical characteristics and treatment of advanced non-small cell lung cancer (NSCLC) patients in China
    Shi, Yuankai
    Zhang, Xin
    Wu, Gang
    Xu, Jianping
    He, Yong
    Wang, Dong
    Huang, Cheng
    Chen, Mingwei
    Yu, Ping
    Yu, Yan
    Li, Wei
    Li, Qi
    Hu, Xiao-hua
    Sun, Guofang
    Li, Yulin
    Bu, Lilian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer
    Divan, Hozefa A.
    Bittoni, Marisa A.
    Krishna, Ashok
    Carbone, David P.
    [J]. BMC CANCER, 2024, 24 (01)
  • [44] Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis
    Kobayashi, Keigo
    Nakachi, Ichiro
    Naoki, Katsuhiko
    Satomi, Ryosuke
    Nakamura, Morio
    Inoue, Takashi
    Tateno, Hiroki
    Sakamaki, Fumio
    Sayama, Koichi
    Terashima, Takeshi
    Koh, Hidefumi
    Abe, Takayuki
    Nishino, Makoto
    Arai, Daisuke
    Yasuda, Hiroyuki
    Kawada, Ichiro
    Soejima, Kenzo
    Betsuyaku, Tomoko
    [J]. CLINICAL LUNG CANCER, 2018, 19 (03) : E349 - E358
  • [45] Real-world treatment patterns of non-small cell lung cancer in an Indian hospital
    Miyasato, Gavin
    Kasivajjala, Vamsi Chandra
    Misra, Mohit
    Kumar, Kiran
    Shah, Chitrang
    Friedman, Howard S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world
    Shi, Yue
    Ji, Min
    Jiang, Yingying
    Yin, Rong
    Wang, Zihan
    Li, Hang
    Wang, Shuaiyu
    He, Kang
    Ma, Yuxin
    Wang, Zhitong
    Lu, Jianwei
    Shi, Meiqi
    Shen, Bo
    Zhou, Guoren
    Leong, Tracy L.
    Wang, Xiaohua
    Chen, Cheng
    Feng, Jifeng
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (06) : 1051 - 1068
  • [47] The efficacy and safety profile of anlotinib plus docetaxel as second-line treatment in advanced non-small cell lung cancer.
    Xu, Zhiqiao
    Zhang, Yan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Efficacy and safety of afatinib in advanced non-small cell lung cancer with EGFR mutations: A real-world study based meta-analysis.
    Zhang, Lemeng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Alonso-Garcia, Miriam
    Sanchez-Gastaldo, Amparo
    Munoz-Fuentes, Miguel A.
    Molina-Pinelo, Sonia
    Boyero, Laura
    Benedetti, Johana Cristina
    Bernabe-Caro, Reyes
    [J]. PHARMACEUTICALS, 2022, 15 (05)
  • [50] Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer
    Le, X.
    Du, R.
    Lewis, W. E.
    Hong, L.
    Skoulidis, F.
    Byers, L.
    Tsao, A.
    Cascone, T.
    Pozadzides, J.
    Tu, J.
    Negrao, M. V.
    Baik, C.
    Zhang, J.
    Heymach, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S484 - S484
12345